A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-cell Receptor Signaling Pathway Inhibitor Therapy
A study for subjects with chronic lymphocytic leukemia using study drug ABT-199
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAN9606
U.S. Govt. ID: NCT02141282
Contact: Grace Lee: 646-317-5205 / gl2536@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate how well the study drug ABT-199 works and safety of ABT-199 in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back (relapsed) after treatment or no response (refractory) to treatment with B-cell receptor signaling pathway inhibitor therapy, namely Ibrutinib and/or Idelalisib. In addition, substances found in the blood, bone marrow and tissue (biomarkers) that may indicate the effects or progress of the leukemia and the activity of ABT-199 will be studied.
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Do you have refractory or relapsed Chronic Lymphocytic Leukemia (CLL)? Yes No
Do you have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Grace Lee
gl2536@cumc.columbia.edu
646-317-5205
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE